ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CARL vs MRK // FORWARD P/E MULTIPLE

Carlsmed Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: CARL 3 — MRK 7
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CARL VS. MRK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CARL MRK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 75.30% 74.80% +0.50 CARL /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 20.70% -55.70 MRK /roic <GO>
EV/EBITDA & P/E Valuation — 15.3x — TIE /valuation <GO>
Free Cash Flow Yield -6.88% 3.42% -10.30 MRK /fcf-yield <GO>
Operating Margin -60.00% 34.30% -94.30 MRK /operating-margins <GO>
Net Profit Margin -58.70% 28.10% -86.80 MRK /net-margins <GO>
Revenue Growth (YoY) — 1.30% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.26% -2.26 MRK /dividend-safety <GO>
Altman Z-Score & Debt/Equity 7.83 5.19 +2.64 CARL /balance-sheet <GO>
Piotroski F-Score Quality 3/9 7/9 -4.00 MRK /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 59.5 51.7 +7.80 CARL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.92 — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — 18.4x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $430.6M $361.02B -$360.59B MRK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CARL REV MRK REV CARL GROSS % MRK GROSS % CARL FCF MRK FCF
FY 2025 $50.5M $65.01B 75.3% 74.8% -$29.6M $12.36B
FY 2024 $27.2M $64.17B 73.8% 76.3% -$25.6M $18.10B
FY 2023 — $60.12B — — — $10.30B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CARL // BETA —
MRK // BETA 0.92